MARATTO

article · SVU-International Journal of Medical Sciences

Role of dihydropyrimidine dehydrogenase genetic polymorphism and vitamin D assay for 5-Fluorouracil therapy in Upper Egypt colorectal cancer patients

Abstract

Background: 5-Fluorouracil (5-FU) is a cornerstone of advanced colorectal cancer (CRC) treatment. Pharmacogenomics variations in DNA may explain why 5-FU is safe for certain people while negatively affecting others. Examination of dihydropyrimidine dehydrogenase (DPYD) allelic variations would aid in improving dose adjustment. The impact of vitamin D on survival has led to the hypothesis that it lowers cancer mortality.Objectives: This work aimed to assess the correlation between 5-FU response and toxicities and their association with DPYD genetic polymorphism and vitamin D levels in CRC patients.Patients and method: A prospective cohort study of 60 CRC patients received 5-FU for 6 months. Patient follow-up to detect clinical adverse effects was done. CBC and liver enzymes were measured before and after treatment. A genotyping study using real-time polymerase chain reaction (PCR) to detect the DPYD*2A (IVS14+1G>A) (rs 3918290) variant was performed. Vitamin D (25(OH)D) serum levels were estimated.Results: There was a significant increase in chest pain, nausea, febrile neutropenia, and bruising among the 5-FU non-responders compared to the responders. The study showed that hemoglobin, WBCs, neutrophils, and platelet counts were significantly higher among 5-FU responders than non-responders. The decrease was higher 6 months post-treatment compared to pre-treatment in responder and non-responder patients. ALT and bilirubin levels were significantly lower among responders than non-responders, the genotyping study indicated the absence of the DPYD*2A variant among the study cases. There was a higher level of vitamin D among 5-FU responders than the non-responders (31.83 ± 4.35, 11.62 ± 4.68 ng/ml) respectively, (p < 0.001).Conclusion: 5-FU efficacy and toxicity were unrelated to DPYD genetic polymorphisms among the study patients. However, there was a strong correlation between vitamin D 5-FU efficacy.

Research topics

  • Colorectal Cancer Treatments and Studies
  • Pancreatic and Hepatic Oncology Research
  • Gastric Cancer Management and Outcomes

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/svuijm.2024.308049.1949

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.